TY - JOUR
T1 - Cancer-Related Fatigue Outcome Measures in Integrative Oncology
T2 - Evidence for Practice and Research Recommendations
AU - Gentile, Danielle
AU - Beeler, Dori
AU - Wang, Xin Shelley
AU - Ben-Arye, Eran
AU - Zick, Suzanna
AU - Bao, Ting
AU - Carlson, Linda E.
AU - Ghelman, Ricardo
AU - Master, Viraj A.
AU - Tripathy, Debu
AU - Zhi, W. Iris
N1 - Funding Information:
member for astraZeneca, aveo, Bayer, Bristol Myers Squibb, Calithera, Caris, Dendreon, Exelixis, Janssen, Pfizer, Merck, Myovant, Novartis, Sanofi, and Tempus; and receives institutional research funding from Bayer and Tempus.
PY - 2022
Y1 - 2022
N2 - Cancer-related fatigue (CRF) is one of the most common symptoms across the cancer continuum and is often underreported and undertreated. Defined as a distressing, persistent, subjective sense of tiredness or exhaustion related to cancer or its treatment, CRF includes physical, emotional, cognitive, and spiritual dimensions. Patient-reported outcome (PRO) measures are the most widely used tool to screen for and assess fatigue and the associated negative impacts on quality of life. However, selecting subjective CRF measures can be complex. This has resulted in the availability of and inconsistent use of numerous PROs, limiting the ability to cross-compare outcomes clinically and within research. To address this, the PROs that are most widely reported in the literature are recommended to support the standardization of a core set of validated measures. The National Comprehensive Cancer Network single-item tool for clinical significance is recommended for quick use in clinical environments; the Brief Fatigue Inventory allows for fast, easy, helpful cutoffs on severity threshold for triage, and measures both severity and interference with daily functioning; while the MD Anderson Symptom Inventory allows for multisymptomatic assessment. In addition, a fundamental consideration for any PRO use is the administrative burden on the patient and clinician. In this review, we aim to summarize current, validated PROs specific to CRF to aid clinicians and researchers in patient care and in study design and implementation. We conclude with suggestions for future directions in CRF research that can increase the possibility for long-term impact on future guidelines of fatigue management.
AB - Cancer-related fatigue (CRF) is one of the most common symptoms across the cancer continuum and is often underreported and undertreated. Defined as a distressing, persistent, subjective sense of tiredness or exhaustion related to cancer or its treatment, CRF includes physical, emotional, cognitive, and spiritual dimensions. Patient-reported outcome (PRO) measures are the most widely used tool to screen for and assess fatigue and the associated negative impacts on quality of life. However, selecting subjective CRF measures can be complex. This has resulted in the availability of and inconsistent use of numerous PROs, limiting the ability to cross-compare outcomes clinically and within research. To address this, the PROs that are most widely reported in the literature are recommended to support the standardization of a core set of validated measures. The National Comprehensive Cancer Network single-item tool for clinical significance is recommended for quick use in clinical environments; the Brief Fatigue Inventory allows for fast, easy, helpful cutoffs on severity threshold for triage, and measures both severity and interference with daily functioning; while the MD Anderson Symptom Inventory allows for multisymptomatic assessment. In addition, a fundamental consideration for any PRO use is the administrative burden on the patient and clinician. In this review, we aim to summarize current, validated PROs specific to CRF to aid clinicians and researchers in patient care and in study design and implementation. We conclude with suggestions for future directions in CRF research that can increase the possibility for long-term impact on future guidelines of fatigue management.
UR - http://www.scopus.com/inward/record.url?scp=85130052910&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85130052910&partnerID=8YFLogxK
U2 - 10.46883/2022.25920958
DO - 10.46883/2022.25920958
M3 - Comment/debate
C2 - 35576178
AN - SCOPUS:85130052910
SN - 0890-9091
VL - 36
SP - 278
EP - 279
JO - ONCOLOGY (United States)
JF - ONCOLOGY (United States)
IS - 5
ER -